We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Extends Review for Skyrizi for Crohn's Disease Indication to Include On-Body Injector Data
FDA Extends Review for Skyrizi for Crohn's Disease Indication to Include On-Body Injector Data
The FDA has extended its review period for AbbVie’s and Boehringer Ingelheim’s Skyrizi (risankizumab-rzaa) for the treatment of moderate-to-severe Crohn's disease in patients age 16 years and older, calling for details of the injector device.